HomeAI · summaries
Storia in 3 fonti
Definium Therapeutics, Inc. Announces Proposed Public Offering
Definium Therapeutics, Inc. Announces Proposed Public Offering
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026
Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026
- ·
benzinga.com
Definium Shares Soar After Reporting Positive Phase 3 Results For Single-Dose Depression Treatment - Defi
Definium shares are surging Monday after the company announced positive topline results from its Phase 3 Emerge study evaluating DT120 orally disintegrating tablet in adults with…
- ·
zerohedge.com
Definium Soars As Much As 50% After LSD-Based Depression Drug Meets Late-Stage Clinical Trial Goal
DT120, a psychedelic that activates serotonin receptors, was generally well tolerated, with mostly mild side effects occurring on dosing day and no serious safety concerns.
- ·
Definium Therapeutics, Inc. Announces Proposed Public Offering
Definium Therapeutics, Inc. Announces Proposed Public Offering
- ·
What's Going On With Definium Therapeutics Stock Tuesday? - Definium Therapeutics (NASDAQ:DFTX)
Definium Therapeutics (DFTX) stock hits $38.24 after positive clinical data, but an 84.57 RSI signals the shares are currently overbought.
- ·
Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering
Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering